We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Spanish drugmaker Grifols has begun a late-stage trial to evaluate its anti-coronavirus hyperimmune globulin, which is derived from the plasma of recovered COVID-19 patients. Read More
Gilead Sciences has released the final results from a late-stage trial of its investigational antiviral remdesivir, which showed that the drug helped patients improve in multiple areas compared to placebo and worked one day faster than previous data showed. Read More
Even President Trump’s top COVID-19 advisers are starting to scale back their timelines for when a vaccine would be ready for Emergency Use Authorization (EUA) or approval despite the president’s assertions to the contrary. Read More
Yet another cancer indication may be in sight for Bristol-Myers Squibb’s blockbuster drug Opdivo (nivolumab) based on the latest results from a phase 3 clinical trial. Read More
The HIV-1 antiviral drug combination lopinavir-ritonavir, marketed by AbbVie under the brand name Kaletra, has shown no benefit in reducing all-cause mortality among patients hospitalized with COVID-19 in the UK’s RECOVERY trial. Read More
GlaxoSmithKline (GSK) and Vir Biotechnology have begun enrolling participants in phase 3 trials to assess the safety and efficacy of their monoclonal antibody, VIR-7831, in treating COVID-19 infections early on in high-risk patients. Read More
The European Medicines Agency’s (EMA) safety committee has begun a review of acute kidney injuries reported in some COVID-19 patients being treated with Gilead Sciences’ remdesivir. Read More
President Trump is being treated with dexamethasone, remdesivir and Regeneron Pharmaceuticals’ investigational antibody cocktail in his battle against COVID-19, following his announcement Friday that he and the first lady had tested positive for the coronavirus. Read More
Pfizer will not allow political arm-twisting to speed up or delay its COVID-19 vaccine candidate trials, the company’s CEO Albert Bourla stressed in an open letter last week. Read More